Navidea Biopharmaceuticals, Inc. (NYSEAMERICAN:NAVB) Sees Significant Growth in Short Interest

Navidea Biopharmaceuticals, Inc. (NYSEAMERICAN:NAVBGet Rating) was the recipient of a large increase in short interest in the month of April. As of April 30th, there was short interest totalling 223,300 shares, an increase of 121.5% from the April 15th total of 100,800 shares. Based on an average trading volume of 385,000 shares, the days-to-cover ratio is currently 0.6 days. Approximately 1.0% of the company’s shares are sold short.

A number of hedge funds have recently bought and sold shares of NAVB. Morgan Stanley increased its position in shares of Navidea Biopharmaceuticals by 84.2% during the first quarter. Morgan Stanley now owns 18,883 shares of the biopharmaceutical company’s stock worth $38,000 after acquiring an additional 8,633 shares in the last quarter. Virtu Financial LLC bought a new stake in Navidea Biopharmaceuticals during the 4th quarter worth approximately $25,000. Finally, Commonwealth Equity Services LLC purchased a new stake in shares of Navidea Biopharmaceuticals in the fourth quarter worth approximately $51,000. 5.22% of the stock is currently owned by institutional investors and hedge funds.

Shares of NAVB traded up $0.05 during trading hours on Friday, hitting $0.77. 24,010 shares of the stock were exchanged, compared to its average volume of 285,175. Navidea Biopharmaceuticals has a fifty-two week low of $0.72 and a fifty-two week high of $2.19. The stock has a market cap of $23.29 million, a PE ratio of -1.97 and a beta of 1.73.

Navidea Biopharmaceuticals (NYSEAMERICAN:NAVBGet Rating) last posted its quarterly earnings data on Wednesday, March 23rd. The biopharmaceutical company reported ($0.12) earnings per share for the quarter. Navidea Biopharmaceuticals had a negative return on equity of 116.36% and a negative net margin of 1,557.43%. The firm had revenue of $0.05 million for the quarter.

Navidea Biopharmaceuticals Company Profile (Get Rating)

Navidea Biopharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates through two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases.

Featured Stories

Receive News & Ratings for Navidea Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Navidea Biopharmaceuticals and related companies with's FREE daily email newsletter.